e-learning
resources
Munich 2014
Monday, 08.09.2014
Pathogenetic mechanisms in pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation
F. Bonella, I. Campo, C. H. M. van Moorsel, M. Griese, J. C. Grutters, U. Costabel, M. Luisetti (Essen, Munich, Germany; Pavia, Italy; Nieuwegein, Netherlands)
Source:
International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Session:
Pathogenetic mechanisms in pulmonary fibrosis
Session type:
Oral Presentation
Number:
1736
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bonella, I. Campo, C. H. M. van Moorsel, M. Griese, J. C. Grutters, U. Costabel, M. Luisetti (Essen, Munich, Germany; Pavia, Italy; Nieuwegein, Netherlands). European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation. Eur Respir J 2014; 44: Suppl. 58, 1736
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Clinical features of four children with pulmonary alveolar proteinosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP)
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014
Aetiological panorama in the diagnosis of interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014
Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts
Source: International Congress 2014 – ILDs 2
Year: 2014
Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia
Source: International Congress 2014 – ILDs 3
Year: 2014
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
Cryptogenic organising pneumonia focusing on its prognostic determinants
Source: International Congress 2014 – ILDs 4
Year: 2014
Asbestos-related disorders (ARDs): Influence of pleural plaques and pulmonary fibrosis due to asbestos exposure on lung function decline (LFD)
Source: International Congress 2014 – ILDs 5
Year: 2014
Mucus production, lung inflammation and functional decay in IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept